EOMES

Across TCGA pan-cancer cohorts, EOMES mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EOMES data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EOMES mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated EOMES expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, LSCC, and HNSC are the cancer types where EOMES mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	1.000	0.390	.023	4	view →
LSCC	OS	Quartile	All	0.996	0.761	.025	3	view →
HNSC	OS	Median	All	0.806	0.599	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

EOMES–LUAD (OS)

Open the LUAD breakdown →